Back to Treatments

Treatment

Ponatinib (for Ph+ ALL)

1
Conditions
20
Trials
4,000
Participants
45%
Average Safety

Condition Evidence

Acute lymphoid leukemia

20 trials · 4,000 participants

83% effectiveness · 45% safety
Ponatinib (for Ph+ ALL) | DFDA